These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 27161705)

  • 1. PO-15 - Antiangiogenic small molecule ligands of FGF2 derived from the endogenous inhibitor thrombospondin-1.
    Pinessi D; Foglieni C; Bugatti A; Moroni E; Resovi A; Ribatti D; Rusnati M; Giavazzi R; Colombo G; Taraboletti G
    Thromb Res; 2016 Apr; 140 Suppl 1():S182. PubMed ID: 27161705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrating computational and chemical biology tools in the discovery of antiangiogenic small molecule ligands of FGF2 derived from endogenous inhibitors.
    Foglieni C; Pagano K; Lessi M; Bugatti A; Moroni E; Pinessi D; Resovi A; Ribatti D; Bertini S; Ragona L; Bellina F; Rusnati M; Colombo G; Taraboletti G
    Sci Rep; 2016 Mar; 6():23432. PubMed ID: 27000667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The calcium-binding type III repeats domain of thrombospondin-2 binds to fibroblast growth factor 2 (FGF2).
    Rusnati M; Borsotti P; Moroni E; Foglieni C; Chiodelli P; Carminati L; Pinessi D; Annis DS; Paiardi G; Bugatti A; Gori A; Longhi R; Belotti D; Mosher DF; Colombo G; Taraboletti G
    Angiogenesis; 2019 Feb; 22(1):133-144. PubMed ID: 30168023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct and allosteric inhibition of the FGF2/HSPGs/FGFR1 ternary complex formation by an antiangiogenic, thrombospondin-1-mimic small molecule.
    Pagano K; Torella R; Foglieni C; Bugatti A; Tomaselli S; Zetta L; Presta M; Rusnati M; Taraboletti G; Colombo G; Ragona L
    PLoS One; 2012; 7(5):e36990. PubMed ID: 22606323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.
    Alessi P; Leali D; Camozzi M; Cantelmo A; Albini A; Presta M
    Eur Cytokine Netw; 2009 Dec; 20(4):225-34. PubMed ID: 20167562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-peptidic thrombospondin-1 mimics as fibroblast growth factor-2 inhibitors: an integrated strategy for the development of new antiangiogenic compounds.
    Colombo G; Margosio B; Ragona L; Neves M; Bonifacio S; Annis DS; Stravalaci M; Tomaselli S; Giavazzi R; Rusnati M; Presta M; Zetta L; Mosher DF; Ribatti D; Gobbi M; Taraboletti G
    J Biol Chem; 2010 Mar; 285(12):8733-42. PubMed ID: 20056600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiangiogenic activity of semisynthetic biotechnological heparins: low-molecular-weight-sulfated Escherichia coli K5 polysaccharide derivatives as fibroblast growth factor antagonists.
    Presta M; Oreste P; Zoppetti G; Belleri M; Tanghetti E; Leali D; Urbinati C; Bugatti A; Ronca R; Nicoli S; Moroni E; Stabile H; Camozzi M; Hernandez GA; Mitola S; Dell'Era P; Rusnati M; Ribatti D
    Arterioscler Thromb Vasc Biol; 2005 Jan; 25(1):71-6. PubMed ID: 15514208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibroblast growth factor-2 antagonist and antiangiogenic activity of long-pentraxin 3-derived synthetic peptides.
    Leali D; Alessi P; Coltrini D; Rusnati M; Zetta L; Presta M
    Curr Pharm Des; 2009; 15(30):3577-89. PubMed ID: 19860702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Undersulfated and glycol-split heparins endowed with antiangiogenic activity.
    Casu B; Guerrini M; Guglieri S; Naggi A; Perez M; Torri G; Cassinelli G; Ribatti D; Carminati P; Giannini G; Penco S; Pisano C; Belleri M; Rusnati M; Presta M
    J Med Chem; 2004 Feb; 47(4):838-48. PubMed ID: 14761186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting tumor angiogenesis with TSP-1-based compounds: rational design of antiangiogenic mimetics of endogenous inhibitors.
    Taraboletti G; Rusnati M; Ragona L; Colombo G
    Oncotarget; 2010 Nov; 1(7):662-673. PubMed ID: 21317461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploiting Surface Plasmon Resonance (SPR) Technology for the Identification of Fibroblast Growth Factor-2 (FGF2) Antagonists Endowed with Antiangiogenic Activity.
    Rusnati M; Bugatti A; Mitola S; Leali D; Bergese P; Depero LE; Presta M
    Sensors (Basel); 2009; 9(8):6471-503. PubMed ID: 22454596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinetic model for FGF, FGFR, and proteoglycan signal transduction complex assembly.
    Ibrahimi OA; Zhang F; Hrstka SC; Mohammadi M; Linhardt RJ
    Biochemistry; 2004 Apr; 43(16):4724-30. PubMed ID: 15096041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro changes in plasma membrane heparan sulfate proteoglycans and in perlecan expression participate in the regulation of fibroblast growth factor 2 mitogenic activity.
    Guillonneau X; Tassin J; Berrou E; Bryckaert M; Courtois Y; Mascarelli F
    J Cell Physiol; 1996 Jan; 166(1):170-87. PubMed ID: 8557766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heparan sulfate proteoglycans function as receptors for fibroblast growth factor-2 activation of extracellular signal-regulated kinases 1 and 2.
    Chua CC; Rahimi N; Forsten-Williams K; Nugent MA
    Circ Res; 2004 Feb; 94(3):316-23. PubMed ID: 14684627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombospondin-1 as a Paradigm for the Development of Antiangiogenic Agents Endowed with Multiple Mechanisms of Action.
    Rusnati M; Urbinati C; Bonifacio S; Presta M; Taraboletti G
    Pharmaceuticals (Basel); 2010 Apr; 3(4):1241-1278. PubMed ID: 27713299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibroblast growth factor signaling pathway in endothelial cells is activated by BMPER to promote angiogenesis.
    Esser JS; Rahner S; Deckler M; Bode C; Patterson C; Moser M
    Arterioscler Thromb Vasc Biol; 2015 Feb; 35(2):358-67. PubMed ID: 25503991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-angiogenic activity of sesterterpenes; natural product inhibitors of FGF-2-induced angiogenesis.
    Hussain S; Slevin M; Matou S; Ahmed N; Choudhary MI; Ranjit R; West D; Gaffney J
    Angiogenesis; 2008; 11(3):245-56. PubMed ID: 18330714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A computational model of fibroblast growth factor-2 binding to endothelial cells under fluid flow.
    Patel NS; Reisig KV; Clyne AM
    Ann Biomed Eng; 2013 Jan; 41(1):154-71. PubMed ID: 22825797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Laminin alpha5 chain metastasis- and angiogenesis-inhibiting peptide blocks fibroblast growth factor 2 activity by binding to the heparan sulfate chains of CD44.
    Hibino S; Shibuya M; Hoffman MP; Engbring JA; Hossain R; Mochizuki M; Kudoh S; Nomizu M; Kleinman HK
    Cancer Res; 2005 Nov; 65(22):10494-501. PubMed ID: 16288042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inflammatory cells and chemokines sustain FGF2-induced angiogenesis.
    Presta M; Andrés G; Leali D; Dell'Era P; Ronca R
    Eur Cytokine Netw; 2009 Jun; 20(2):39-50. PubMed ID: 19541589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.